Most clinics that offer compounded medications end up working with more than one pharmacy. One pharmacy is licensed in Texas but not California; another prepares the dosage form a patient needs; a third is the only source of office-use stock. The ordering software that sits in front of those pharmacies decides how much of that complexity lands on your staff. After the FDA's 2026 enforcement actions, it also decides how much compliance exposure your prescribing workflow carries.
This guide is a neutral checklist for clinics, med spas, men's health practices and telehealth companies evaluating compounding pharmacy ordering platforms. It covers the main kinds of platform, the criteria that matter, the questions to ask a vendor and the red flags that should end a conversation. It does not rank vendors.
What a Compounding Pharmacy Ordering Platform Does
A compounding pharmacy ordering platform is software that lets a practice place compounded-medication orders with one or more licensed pharmacies from a single interface. Depending on the platform, that can include a product catalog, patient records, e-prescribing, payment, shipping and order tracking.
Two things it is not:
- It is not the pharmacy. Compounding, dispensing and most of the regulatory responsibility sit with the licensed 503A pharmacy or 503B outsourcing facility that fills the order. Every vendor should be able to tell you plainly who dispenses.
- It is not the prescriber. The clinical decision, and the documentation behind it, belongs to the licensed prescriber. Software that blurs that line is a liability, as the section on the 2026 rules explains.
The Four Kinds of Platform
| Type | What it is | Works well when | Watch for |
|---|---|---|---|
| Single-pharmacy portal | The ordering website of one pharmacy | You need one pharmacy and it is licensed everywhere your patients are | Gaps in state licensing; no alternative when a product is backordered |
| Multi-pharmacy ordering platform | One catalog in front of several independent pharmacies | You treat patients in many states or need products no single pharmacy offers | How pharmacies join, what each is licensed for, and how pricing is shown |
| E-prescribing or EHR module | Compounded ordering inside a prescribing or charting system | Your prescribers already work in that system | Narrow pharmacy choice and limited order tracking |
| White-label telehealth stack | A branded patient-facing front end with pharmacy fulfillment behind it | You run a direct-to-patient telehealth brand | Who controls prescribing, and whether formulations come pre-packaged |
Many practices combine two of these, for example a multi-pharmacy platform for patient prescriptions and an outsourcing facility's own portal for office stock. The checklist below applies to all of them.
The Checklist
1. State licensing matched to the patient
A 503A pharmacy can only ship to states where it holds an active license. The platform should know each pharmacy's licensed states and match every order to the patient's ship-to state, instead of leaving staff to maintain a licensing spreadsheet. Ask how often licensing data is updated and what happens to open orders when a license lapses.
2. Both 503A and 503B, if you need office stock
Patient-specific prescriptions come from 503A pharmacies. Stock for in-office administration can only come from FDA-registered 503B outsourcing facilities, usually after a facility-level enrollment. If your practice administers medications on site, check whether the platform handles 503B enrollment and keeps office-use orders separate from patient prescriptions. The 503B office-use ordering guide explains the difference in detail.
3. E-prescribing, including controlled substances
If you prescribe testosterone or any other controlled substance, the platform needs EPCS: electronic prescribing that meets DEA requirements, with identity proofing and two-factor signing. Without it, controlled prescriptions fall back to paper or phone and your workflow splits in two.
4. Prescriber control and individual documentation
Every order should start from an identified patient, and the prescriber should write the prescription and the clinical notes for that patient. The platform should not pre-fill a formulation, a "significant difference" statement or any other justification. This matters more in 2026 than it ever has.
5. Transparent pricing
You should see each pharmacy's price before ordering, along with any platform fee, shipping and payment-processing cost. Ask whether the platform marks up pharmacy pricing and how that is disclosed.
6. Payment models that fit your practice
Some practices pay the pharmacy and bill patients themselves; others want patients to pay at checkout. A platform that supports both lets you change models without changing tools.
7. Tracking, refills and patient communication
Look for one order list across every pharmacy, statuses from pharmacy review through delivery, tracking links patients can follow, and refills tied to the original prescription.
8. Records you can produce on request
Boards of pharmacy and the FDA ask for prescriptions, clinical rationale and order history. The platform should retain prescriptions, order records and receipts per patient and per practice, and let you export them.
9. Pharmacy quality signals
The platform does not compound anything itself, so ask what it knows about the pharmacies behind it: state licensure and standing, USP <797> and <800> compliance for sterile and hazardous preparations, potency, sterility and endotoxin testing, and, for 503B facilities, FDA registration and inspection history. Then ask the pharmacies directly. Quality diligence is not something a clinic can delegate.
10. Security, access control and integrations
Expect a business associate agreement (BAA) under HIPAA, user roles so staff see only what they need, support for multiple locations and prescribers, and an API if you run your own patient-facing software.
Questions to Ask Any Vendor
- Who dispenses each order, and is every pharmacy on your platform independently licensed?
- How do you track each pharmacy's licensed states, and how is an order matched to the patient's state?
- Do you support 503B office-use ordering, and how does facility enrollment work?
- Do you support EPCS for controlled substances?
- Does your platform ever pre-select a formulation or pre-fill a significant-difference statement for the prescriber?
- How is pharmacy pricing displayed, and what fees do you add?
- What records do you keep per patient and per practice, and how do we export them?
- Will you sign a BAA?
- What happens to open orders if a pharmacy leaves your network or a product is backordered?
- How do you handle substances whose regulatory status is unsettled, such as peptides under FDA review?
Red Flags
- Pre-packaged GLP-1 menus. Standard bundles of a GLP-1 with a vitamin or other additive, offered as a default instead of a prescriber's patient-specific choice. The FDA has treated products like these as essentially copies of approved drugs.
- Pre-filled justifications. Templated "significant difference" language applied to every patient.
- Research-use chemicals. Products labeled "not for human consumption" are not pharmaceuticals, and the label does not protect a clinic that administers them.
- Investigational drugs offered as compounded. An offer of "compounded retatrutide" is a red flag about the seller; there is no lawful compounding pathway for it. See the retatrutide regulatory status fact check.
- No state-licensing logic. If the platform cannot tell you which pharmacy can ship to which state, your staff will end up doing it by hand.
- Unclear dispensing. If you cannot get a straight answer about which licensed pharmacy fills an order, walk away.
How the 2026 Rules Change What to Look For
Three developments in 2026 shifted platform evaluation from convenience toward compliance:
- April 1, 2026. The FDA restated its "essentially a copy" policy and used semaglutide plus vitamin B12 as its example of a compounded product it may treat as a copy of an approved drug when the route matches and the strengths are close to the commercial products.
- April 30, 2026. The FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. Outsourcing facilities cannot compound those drugs from bulk today, so a platform offering them as office stock is a warning sign. See the 503B bulks list proposal explained.
- September 18, 2026. The FDA's warning letter to a large compounding pharmacy said its production volume suggested the claimed differences in its GLP-1 combinations were pretextual, criticized templated significant-difference language, and pointed to third-party platforms that offer prescribers pre-selected options. See the warning letter explained.
The practical effect is that your ordering platform is now part of your compliance posture. A platform that starts from the patient, leaves the prescription and its rationale to the prescriber, and keeps a clean record of both is far easier to defend than one built around a product menu.
A Simple Scorecard
| Criterion | Priority |
|---|---|
| Pharmacy licensing matched to the patient's state | Must have |
| Prescriber writes and documents every prescription; no pre-selected formulations | Must have |
| Clear answer on who dispenses each order | Must have |
| Prescription and order records retained and exportable | Must have |
| BAA and role-based user access | Must have |
| EPCS for controlled substances | Must have if you prescribe them |
| 503B office-use ordering with facility enrollment | Must have if you administer in the office |
| Pharmacy pricing and all fees shown before ordering | Should have |
| Clinic-pay and patient-pay options | Should have |
| Several pharmacies per product, with alternatives when one is backordered | Should have |
| API and multi-location support | Nice to have; essential for telehealth companies |
Where ScriptLinkRx Fits
ScriptLinkRx is a multi-pharmacy ordering platform: one catalog in front of independently licensed 503A compounding pharmacies and 503B outsourcing facilities, with orders matched to each patient's state, EPCS e-prescribing, clinic-pay or patient-pay checkout and order tracking. It does not compound or dispense, and it does not pre-select formulations. Hold it to the checklist above as you would any vendor; the partner pharmacy network and the 503A ordering guide show how it works.
Sources
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 1, 2026)
- FDA: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026)
- FDA: Warning Letters (search "Empower Clinic Services", September 18, 2026)
- FDA: Compounding and the FD&C Act (sections 503A and 503B)
- FDA: Registered Outsourcing Facilities
- DEA: Electronic Prescriptions for Controlled Substances (EPCS)
- HHS: Business Associates under HIPAA